找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Asthma: Targeted Biological Therapies; Girolamo Pelaia,Alessandro Vatrella,Rosario Masell Book 2017 Springer International Publishing Swit

[復(fù)制鏈接]
樓主: 突然
21#
發(fā)表于 2025-3-25 05:28:04 | 只看該作者
22#
發(fā)表于 2025-3-25 08:36:46 | 只看該作者
Conclusions and Future Perspectives,rapies, many of which are undergoing advanced stages of clinical investigation, will probably lead in the next future to the introduction in real life of several other biologics indicated for asthma treatment [7–11].
23#
發(fā)表于 2025-3-25 12:07:51 | 只看該作者
https://doi.org/10.1007/978-3-8348-9214-0 different responses to pharmacological therapies [5, 6]. The majority of asthmatic patients can achieve a good control of their symptoms using standard treatments including inhaled corticosteroids and bronchodilators such as β.-adrenergic agonists, as well as oral leukotriene inhibitors [7, 8].
24#
發(fā)表于 2025-3-25 18:17:28 | 只看該作者
https://doi.org/10.1007/978-3-658-30557-4 this key immunological discovery into the approval of the anti-IgE antibody omalizumab for the treatment of severe allergic asthma [7]. Indeed, omalizumab has been the first and for a long time the only biologic drug available in clinical practice for add-on therapy of uncontrolled asthma [8].
25#
發(fā)表于 2025-3-25 22:15:23 | 只看該作者
Wilfried Pla?mann,Detlef Schulzeroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma [8]. Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
26#
發(fā)表于 2025-3-26 00:52:45 | 只看該作者
27#
發(fā)表于 2025-3-26 08:20:12 | 只看該作者
28#
發(fā)表于 2025-3-26 09:47:47 | 只看該作者
IL-5-Targeted Antibodies,eroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma [8]. Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
29#
發(fā)表于 2025-3-26 14:31:16 | 只看該作者
30#
發(fā)表于 2025-3-26 19:00:20 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-11-1 04:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
甘德县| 安岳县| 慈溪市| 林甸县| 霞浦县| 临安市| 麟游县| 乐平市| 龙口市| 临海市| 凭祥市| 调兵山市| 三原县| 甘洛县| 呼图壁县| 九龙城区| 乌兰县| 平安县| 班戈县| 黑龙江省| 大丰市| 凉城县| 尉犁县| 扶沟县| 池州市| 阿图什市| 越西县| 虞城县| 含山县| 富宁县| 平阴县| 山丹县| 拜泉县| 灌阳县| 方山县| 湖南省| 逊克县| 武汉市| 达拉特旗| 天全县| 穆棱市|